Brief: Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing
BRIEF-Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing Oct 19 (Reuters) - Curanex Pharmaceuticals Inc CURX.O:
CURANEX PHARMACEUTICALS - SECURITIES CLASS ACTION FILED AGAINST CURANEX PHARMACEUTICALS AND UNDERWRITERS ON JULY 23, 2026 - SEC FILING
CURANEX PHARMACEUTICALS - PROPOSED CLASS INCLUDES PERSONS WHO BOUGHT CURANEX SECURITIES IN AUGUST 2025 IPO - SEC FILING
CURANEX PHARMACEUTICALS - COMPLAINT ALLEGES MISSTATEMENTS AND OMISSIONS REGARDING STOCK-PRICE MANIPULATION RISKS - SEC FILING
CURANEX PHARMACEUTICALS - SEPARATE SECURITIES CLASS ACTION FILED AGAINST CURANEX, FORMER CFO, DIRECTORS, AUDITOR, AND UNDERWRITERS - SEC FILING
CURANEX PHARMACEUTICALS - DEADLINE TO RESPOND TO MORALES COMPLAINT EXTENDED TO NOVEMBER 15, 2026 - SEC FILING
CURANEX PHARMACEUTICALS - DEADLINE TO RESPOND TO LOVETT COMPLAINT EXTENDED TO DECEMBER 11, 2026 - SEC FILING
Source text: [ID:n0001493152-26-047614]
Further company coverage: CURX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Curanex Pharmaceuticals
See all newsBrief: Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Curanex Pharmaceuticals Advancing Phyto-N Toward A Planned Investigational New Drug Submission To FDA For Ulcerative Colitis In Q4 2026